Category: Uncategorized

• What Counts as a Serious Adverse Event
• The Sponsor's Core Obligations
  • 1. Receiving and Acknowledging Reports from Sites
  • 2. Assessing Causality and Expectedness
  • 3. Reporting to the FDA
  • 4. Reporting to Ethics Committees and Local Authorities
• SAE Reporting Timelines at a Glance
• What a Well-Structured SAE Report Contains
• Common Mistakes Sponsors Make
• SAE Reporting in First-in-Human Trials: Specific Considerations
• Building an SAE Reporting Plan Before Your Trial Starts
• FAQs

Serious adverse events are a reality of clinical research. How your team responds in the hours and days after one occurs can determine whether your trial stays on schedule, whether your regulatory submission holds up, and whether your relationship with the FDA remains intact.

For startup sponsors running first-in-human studies, the stakes are especially high. You may not have a dedicated safety pharmacovigilance team. Your CRO may be managing the reporting workflow on your behalf. Either way, the sponsor remains legally accountable for every SAE report that goes to the FDA, the ethics committee, and the host country authority.

This article covers what an SAE is, what triggers reporting obligations, what the timelines look like, and what a well-run SAE process actually requires.

What Counts as a Serious Adverse Event

An adverse event is any untoward medical occurrence in a trial participant. An SAE is a specific subset, defined by outcome criteria. Under FDA definitions and ICH-GCP standards, an adverse event qualifies as serious if it results in any of the following:

• Death
• A life-threatening condition
• Inpatient hospitalization or prolongation of existing hospitalization
• Persistent or significant disability or incapacity
• A congenital anomaly or birth defect
• A medically important event that may not meet the above criteria but could jeopardize the participant and require medical or surgical intervention to prevent one of the above outcomes

That last category — "medically important events" — is where sponsor judgment gets tested. It requires real clinical and regulatory expertise to assess correctly, and errors in either direction create problems. Under-reporting exposes you to regulatory action; over-reporting can signal poor protocol design or weak site management.

The Sponsor’s Core Obligations

Sponsors bear primary responsibility for SAE reporting, even when a CRO is handling day-to-day trial operations. FDA regulations under 21 CFR Part 812 (for devices) and 21 CFR Part 312 (for drugs and biologics) make this unambiguous.

Sponsor obligations generally fall into four categories.

1. Receiving and Acknowledging Reports from Sites

Investigators are required to report SAEs to the sponsor promptly — typically within 24 hours of becoming aware of the event. Your trial protocol should define the exact reporting pathway: who the investigator contacts, what form or system they use, and what information must be included in the initial report.

A missing or delayed investigator report does not relieve the sponsor of its own reporting obligations. You are expected to have systems in place to capture SAEs regardless of whether sites report on time.

2. Assessing Causality and Expectedness

Once you receive an SAE report, your medical monitor or safety team must assess two things: whether the event is reasonably related to the investigational product or device, and whether it was anticipated based on the current risk profile documented in your Investigator's Brochure or device description.

An unexpected serious adverse device effect (SADE) in a medical device trial, or an unexpected serious adverse reaction (USAR) in a drug trial, triggers expedited reporting requirements. Expected SAEs still require documentation and submission — just on a different timeline.

3. Reporting to the FDA

For investigational device exemption (IDE) trials, sponsors must report unanticipated adverse device effects (UADEs) to the FDA and all reviewing IRBs within 10 working days of first receiving notice of the effect.

For IND-covered drug and biologic trials, unexpected fatal or life-threatening suspected unexpected serious adverse reactions (SUSARs) must be reported within 7 calendar days. All other unexpected SUSARs go to the FDA within 15 calendar days.

These are not soft targets. Missing a reporting window is a protocol deviation that must itself be documented and may trigger an FDA inquiry.

4. Reporting to Ethics Committees and Local Authorities

Beyond FDA reporting, you must notify the IRB or ethics committee that approved the study. Local requirements in the country where the trial is being conducted also apply.

For trials running in Latin American jurisdictions, this means notifying the relevant national authority alongside the ethics committee. In Panama, that involves MINSA/CNBI. In Chile, ISP/MINSAL. In El Salvador, SRS/CNEIS. Each authority has its own SAE reporting format and timeline requirements — all of which need to be built into your safety management plan before the trial starts.

SAE Reporting Timelines at a Glance

These timelines run from the date the sponsor first becomes aware of the event — not from when the investigator first observed it. The clock starts the moment information reaches your organization.

What a Well-Structured SAE Report Contains

An incomplete SAE report is nearly as problematic as a late one. The FDA and ethics committees expect the following elements in an expedited report:

• Patient identifiers (coded, not personally identifiable)
• Event description: onset date, duration, severity, and outcome
• Causality assessment: the sponsor's determination of whether the event is related to the investigational product
• Expectedness assessment: whether the event was anticipated based on current risk documentation
• Action taken: whether the protocol was modified, the participant discontinued, or the device retrieved
• Investigator's narrative: the site-level account of what happened
• Sponsor's narrative: the sponsor-level analysis, including any signal implications for the broader study population

For device trials following ISO 14155 architecture, the report structure also needs to align with risk management documentation. An SAE that reveals a failure mode not previously identified in your risk analysis requires a formal update to that analysis — not just a safety report.

Common Mistakes Sponsors Make

Most SAE reporting failures follow a small number of patterns.

Delayed internal escalation. Sites report to the CRO, but internal routing takes two days before the sponsor's medical monitor sees the event. By then, the reporting window is already compressed.

Causality assessed too narrowly. Sponsors sometimes default to "unrelated" assessments to avoid expedited reporting obligations. Regulatory reviewers are experienced at identifying patterns across a trial population, and a string of "unrelated" SAEs that share a mechanism will draw scrutiny.

Inadequate follow-up reporting. An initial expedited report is not the end of the obligation. Follow-up reports must be submitted as new information becomes available, until the event resolves or the outcome is confirmed. Sponsors who file an initial report and then go quiet on a case create audit flags.

Inconsistent definitions across sites. If your protocol does not define SAE criteria precisely, different investigators will apply different thresholds — and you end up with inconsistent safety data that complicates your eventual submission.

No pre-defined escalation path for ambiguous events. Medical monitors need a documented decision tree for events that sit at the boundary of the SAE definition. Without one, each ambiguous case becomes an ad hoc discussion, which slows reporting and introduces inconsistency.

SAE Reporting in First-in-Human Trials: Specific Considerations

First-in-human studies carry a higher baseline uncertainty than later-phase trials. The safety profile of the device or compound is, by definition, not yet established in humans — which means your SAE reporting infrastructure needs to be especially robust from day one.

A few things matter more at the FIH stage than they do later.

Your Investigator's Brochure or device description must be current. Expectedness assessments depend on what your IB documents as known or anticipated risks. An out-of-date IB means you may misclassify expected events as unexpected, or miss the significance of something that should have been flagged.

Your DSMB or Safety Review Committee needs clear SAE triggers. Define in advance what event types or frequencies will prompt an unscheduled safety review or a protocol hold recommendation. Leaving this to judgment in the moment creates delays and inconsistency.

Your evidence package must capture SAE data in a submission-ready format. If your goal is an IDE, 510(k), or PMA submission, the safety data from your FIH study needs to be organized so that FDA reviewers can evaluate it efficiently. An SAE narrative that reads well in a site file but isn't structured for regulatory review will slow your submission.

For sponsors running trials in Latin American jurisdictions, the SAE data also needs to meet FDA's requirements for foreign clinical data under 21 CFR 812.28. That means the safety reporting process must be designed with FDA acceptance in mind from the start — not retrofitted after the trial closes.

bioaccess® structures all FIH-12™ program safety workflows around this requirement. The nine-workstream engagement includes data management and final evidence package delivery specifically designed to produce a submission-ready safety record for the sponsor's next FDA regulatory step — whether that is an IDE, 510(k), De Novo, or PMA. You can learn more at bioaccess®.

Building an SAE Reporting Plan Before Your Trial Starts

The time to design your SAE reporting process is during protocol development — not after your first event occurs. A functional SAE reporting plan addresses the following:

• Definitions: Exact criteria for what constitutes an SAE in your specific trial, including the "medically important events" category
• Reporting pathways: How investigators report to the sponsor, what system or form they use, and what the acknowledgment process looks like
• Internal routing: Who in the sponsor organization receives the report, who performs the causality assessment, and who signs the expedited report to FDA
• Timeline tracking: A system that logs the date the sponsor first became aware of each event and tracks the reporting deadline automatically
• Local authority requirements: Country-specific reporting formats and timelines for each jurisdiction where the trial is running
• Follow-up procedures: Who is responsible for obtaining outcome information and filing follow-up reports
• Annual safety reporting: How individual SAE data rolls up into the annual progress report or Development Safety Update Report (DSUR)

Getting this infrastructure in place before enrollment starts is not a bureaucratic exercise. It protects your participants, protects your data, and protects your regulatory pathway.

FAQs

What is the difference between an adverse event and a serious adverse event?
An adverse event is any untoward medical occurrence in a trial participant, regardless of severity. A serious adverse event meets at least one of a defined set of outcome criteria: death, life-threatening condition, hospitalization, significant disability, congenital anomaly, or a medically important event requiring intervention to prevent a serious outcome. Not all adverse events require expedited reporting; SAEs do.

Who is responsible for SAE reporting in a sponsored clinical trial?
The sponsor holds primary legal responsibility for SAE reporting to the FDA and ethics committees, even when a CRO manages day-to-day operations. The investigator is responsible for reporting SAEs to the sponsor promptly — typically within 24 hours. The sponsor then assesses the event and files the required regulatory reports within the applicable deadlines.

What is the FDA reporting deadline for an unanticipated adverse device effect in an IDE trial?
Sponsors must report unanticipated adverse device effects (UADEs) to the FDA and all reviewing IRBs within 10 working days of first receiving notice of the effect.

Does SAE reporting work the same way in Latin American trial jurisdictions as it does in the US?
The FDA reporting obligations remain the same regardless of where the trial is conducted. In addition, sponsors must comply with the SAE reporting requirements of each host country's national authority. In Panama, Chile, and El Salvador, separate notifications to MINSA/CNBI, ISP/MINSAL, and SRS/CNEIS respectively are required. A well-designed safety management plan accounts for both sets of obligations simultaneously.

Can foreign clinical trial SAE data be used in a US regulatory submission?
Yes, provided the data is collected and documented in accordance with FDA's requirements for foreign clinical data. For device trials, 21 CFR 812.28 governs the acceptance of foreign data. The safety record must be structured to meet FDA review standards — which requires intentional design from the start of the trial, not after the fact.

What happens if a sponsor misses an SAE reporting deadline?
Missing a reporting deadline is a protocol deviation that must be documented and reported. Depending on the severity of the event and the length of the delay, the FDA may issue a clinical hold, request a corrective action plan, or flag the deviation during a pre-submission review. Repeated reporting failures can jeopardize the entire trial program.

How should sponsors handle SAEs that are ambiguous about whether they meet the "serious" threshold?
Your protocol should include a pre-defined decision process for ambiguous events, including escalation to a medical monitor or safety officer. When in doubt, the default should be to treat the event as serious and report it. Over-reporting a borderline event is a far smaller regulatory risk than under-reporting one that later proves significant.

SAE reporting is not a back-office compliance task. It is a core part of how you demonstrate that your trial is being conducted with scientific rigor and participant safety as the priority. Build the infrastructure before your first patient is enrolled, train your sites on the process, and make sure your CRO's safety workflows are designed to produce data that will hold up in a regulatory submission.

If you are planning a first-in-human study and want to understand how SAE reporting fits into a structured trial program, bioaccess® manages the full safety workflow as part of the FIH-12™ engagement.

• Why Sequencing Matters More Than Speed Alone
• Understand Your FDA Pathway First
  • The Five Core Pathways
• The FDA Framework That Makes LATAM Data Count
• Choosing the Right LATAM Jurisdiction for Your Device
  • Fast-Approval Jurisdictions
  • What Drives Jurisdiction Selection
• How to Sequence the Two Tracks
  • Phase 1: FDA Strategy Alignment (Months 1 to 2)
  • Phase 2: Protocol Development and Jurisdiction Selection (Months 2 to 3)
  • Phase 3: Site Activation and Enrollment (Months 3 to 8)
  • Phase 4: Evidence Package Assembly (Months 8 to 12)
• The Startup-Specific Consideration: Runway and Milestones
• Common Sequencing Mistakes to Avoid
• How bioaccess® Structures This for Sponsors
• FAQs
• Where to Start

WordPress Category: Navigating Regulatory Landscapes in Latin America

Most MedTech founders treat regulatory strategy as a linear problem: get FDA clearance, then figure out the rest. That framing costs time and money. The smarter approach treats your FDA pathway and your first-in-human data strategy as a single sequenced plan — not two separate workstreams running independently.

If you're a startup CEO or CSO sitting on an IDE approval or approaching a Series A close, this article walks through how to think about that sequence, why Latin American regulatory jurisdictions belong in your plan, and how to structure the evidence you generate so it holds up at every step.

Why Sequencing Matters More Than Speed Alone

Speed is the obvious reason founders look at Latin America. Ethics and regulatory approvals in jurisdictions like Panama, El Salvador, Chile, and the Dominican Republic take 30 to 90 days, compared to 6 to 12 months in the US. That gap alone can determine whether you have first human data before your next funding round closes — or after it.

But speed without regulatory alignment creates its own problem. If your LATAM trial isn't structured to FDA's foreign clinical data requirements from day one, the data you generate may not be usable for your IDE, 510(k), De Novo, or PMA submission. You'll have spent the time and the budget, and FDA will ask for more.

The goal isn't just to run a trial fast. It's to generate a submission-ready evidence package that bridges directly to your next FDA step.

Understand Your FDA Pathway First

Before you select a country, a site, or a protocol design, you need to know which FDA pathway your device is targeting. That determination shapes everything downstream.

The Five Core Pathways

IDE (Investigational Device Exemption): Required for significant risk devices entering US clinical investigation. LATAM FIH data can support the IDE application or inform the protocol for the US pivotal study that follows.

510(k): Clearance through substantial equivalence to a predicate device. First-in-human data from a LATAM feasibility study can strengthen a 510(k) by demonstrating clinical performance in a controlled setting.

De Novo: For novel low-to-moderate risk devices with no predicate. The clinical evidence standard is higher than 510(k), and a well-documented LATAM FIH study can serve as the primary clinical evidence basis.

PMA (Premarket Approval): For high-risk Class III devices. LATAM FIH and early feasibility data typically forms the foundation for a subsequent US pivotal study. The quality of your early data directly affects how FDA evaluates your pivotal protocol.

HDE (Humanitarian Device Exemption): For rare disease devices affecting fewer than 8,000 US patients annually. Early clinical data from a LATAM feasibility study can satisfy the probable benefit standard.

Knowing your pathway tells you what evidence FDA will need — which tells you what your LATAM protocol must produce.

The FDA Framework That Makes LATAM Data Count

Under FDA 21 CFR 812.28 (see FDA's official page on Acceptance of Data from Clinical Investigations for Medical Devices), data from foreign clinical investigations of medical devices may be accepted in support of an IDE or marketing submission, provided the study was conducted in accordance with Good Clinical Practice, including review and approval by an independent ethics committee, and the sponsor can verify data quality and integrity.

This isn't a loophole. It's a documented, established framework. What it requires is that your LATAM study be designed and executed to the same quality standard you'd apply to a US study — ISO 14155 protocol architecture, ICH-GCP compliance, independent ethics review, and an audit-ready data room.

If any of those elements are missing or inconsistently applied, the data's usability for FDA submissions becomes uncertain. This is exactly why protocol design and regulatory strategy must be aligned before enrollment begins, not after.

Choosing the Right LATAM Jurisdiction for Your Device

Not every Latin American country offers the same regulatory environment. For a startup, the practical distinction comes down to approval timeline and regulatory body predictability.

Fast-Approval Jurisdictions

Panama (MINSA/CNBI): Consistently among the fastest ethics and regulatory approval timelines in the region. Well-suited for first-in-human feasibility studies across a broad range of device classes.

El Salvador (SRS/CNEIS): Regulatory approvals in the 30-to-90-day range. A strong option for sponsors who need to move quickly and have a straightforward device profile.

Dominican Republic: Comparable approval timelines, with a growing clinical research infrastructure.

Chile (ISP/MINSAL): A slightly more structured process, but still substantially faster than US timelines. Well-regarded for cardiovascular and interventional device studies.

Colombia: An established clinical research ecosystem with experienced investigator networks, particularly for complex device categories.

What Drives Jurisdiction Selection

Three factors should drive your choice: the device class and indication (some jurisdictions have deeper investigator experience in specific specialties), the regulatory body's familiarity with your device category, and your target FDA pathway. A device heading toward De Novo has different evidence requirements than one supporting a PMA, and those differences affect which jurisdiction and site network best fits your protocol.

How to Sequence the Two Tracks

Here's a practical sequencing framework for a startup that is IDE-ready or approaching that milestone.

Phase 1: FDA Strategy Alignment (Months 1 to 2)

Before any country selection or protocol drafting, align your LATAM study design to your FDA pathway. That means defining the primary and secondary endpoints your submission will need, confirming the study design (feasibility vs. pivotal), and identifying what a Pre-Submission meeting with FDA should accomplish before you enroll the first patient.

If you haven't had a Pre-Sub meeting yet, this is the time. The output of that meeting shapes your protocol. Running a LATAM study without it is a sequencing error that's difficult to correct after the fact.

Phase 2: Protocol Development and Jurisdiction Selection (Months 2 to 3)

With FDA alignment in place, develop your protocol under ISO 14155 architecture. Select your LATAM jurisdiction based on device class, indication, and approval timeline requirements, then submit to the relevant ethics committee and regulatory authority.

In Panama, El Salvador, and the Dominican Republic, ethics and regulatory approvals typically come back within 30 to 90 days of a complete submission. That window is your planning horizon for site activation.

Phase 3: Site Activation and Enrollment (Months 3 to 8)

Activate pre-qualified sites, enroll patients, and collect data under ICH-GCP standards with audit-ready documentation at every step.

The quality of your data management during this phase determines how clean your evidence package will be. Errors in data collection that seem minor during enrollment tend to become significant problems during FDA review.

Phase 4: Evidence Package Assembly (Months 8 to 12)

Compile your clinical study report, statistical analysis, and organized data room structured for your specific FDA next step. Whether that's an IDE application, a 510(k) submission, or the clinical evidence section of a PMA, the deliverable should be organized to FDA's expectations — not just internally coherent.

The Startup-Specific Consideration: Runway and Milestones

For a seed-to-Series-B startup, the regulatory strategy question is inseparable from the capital question. Your investors have a milestone schedule. Your board has a timeline. Your next round has a closing date.

A US CRO timeline of 18 to 24 months for first human data doesn't fit inside a typical startup runway. A LATAM FIH study structured for FDA bridgeability can deliver a submission-ready evidence package within 12 months under the right program structure. That difference is often the difference between having data for your Series B and not having it.

This isn't an argument to cut corners on quality. It's an argument to select the regulatory jurisdictions and execution model that match your actual timeline constraints — without compromising the standards that make the data usable.

Common Sequencing Mistakes to Avoid

Starting protocol development before confirming your FDA pathway. If you don't know whether you're targeting a De Novo or a PMA, you can't write the right protocol. The evidence standard is different, and rewriting a protocol after enrollment has started is expensive.

Selecting a jurisdiction for speed alone. A fast approval timeline only matters if the site network in that jurisdiction has genuine experience with your device category and can execute to ISO 14155 standards. Speed and quality aren't mutually exclusive, but they require deliberate site selection.

Treating the LATAM study as separate from the FDA strategy. Every decision in your LATAM trial — from endpoint selection to data collection procedures — should be made with your FDA submission in mind. The two tracks are one plan.

Underestimating the data room requirement. FDA reviewers expect organized, auditable data. A clinical study report that's internally coherent but not structured for FDA review creates unnecessary friction at submission. Build the data room to FDA's expectations from the start.

How bioaccess® Structures This for Sponsors

bioaccess® is a CRO that manages first-in-human clinical trials for MedTech, Biopharma, and Radiopharma startups through exactly this kind of sequenced approach. The FIH-12™ program covers all nine workstreams — from FDA strategy alignment and protocol development through site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package — within 12 months.

One accountable team manages all nine workstreams across a network of 50-plus pre-qualified sites in Panama, Colombia, El Salvador, Chile, and the Dominican Republic. Every study is anchored to the sponsor's intended FDA pathway from day one, and the final deliverable is a clinical study report and organized data room structured for the sponsor's next FDA step.

Intake is limited to a maximum of eight new programs per quarter — worth factoring into your planning timeline.

FAQs

Does FDA actually accept clinical data from Latin American trials?
Yes. Under FDA 21 CFR 812.28, data from foreign clinical investigations of medical devices may be accepted in support of IDE and marketing submissions, provided the study was conducted in accordance with Good Clinical Practice and the sponsor can verify data quality and integrity. The key requirement is that the study is designed and executed to the same standards FDA would expect from a US study.

How long do regulatory approvals take in Panama, El Salvador, and the Dominican Republic?
Ethics and regulatory approvals in these jurisdictions typically take 30 to 90 days from a complete submission. That refers to the approval process specifically, not the overall trial duration.

What is the difference between a feasibility study and a pivotal study in this context?
A feasibility study evaluates the preliminary safety and performance of a device in a small patient population. A pivotal study generates the primary clinical evidence for a marketing submission. For most startups, the LATAM FIH study is a feasibility study that informs and supports the subsequent US pivotal study.

Can LATAM FIH data support a 510(k) submission directly?
In some cases, yes. If the 510(k) requires clinical data to demonstrate substantial equivalence, a well-documented LATAM feasibility study conducted under ISO 14155 and ICH-GCP standards can serve as that clinical evidence. The specific requirements depend on the device class and the predicate.

What is ISO 14155 and why does it matter for FDA submissions?
ISO 14155 is the international standard for Good Clinical Practice in clinical investigations of medical devices. FDA recognizes it as the applicable GCP standard for medical device trials, and studies conducted under its framework are structured to meet FDA's foreign clinical data acceptance requirements under 21 CFR 812.28.

When should a startup begin thinking about LATAM regulatory strategy?
Ideally, before protocol development begins. The earlier you align your LATAM study design to your FDA pathway, the less rework you'll face later. For most startups, the right entry point is at or shortly after an IDE approval or Series A close, when both the capital and the regulatory authorization to proceed are in place.

What happens if the LATAM jurisdiction doesn't have experienced investigators for my device category?
This is a real risk — and a reason why jurisdiction selection should be based on more than approval timelines alone. Site networks with documented experience in your device category reduce protocol execution risk. Evaluating investigator experience and site qualification before finalizing your jurisdiction is an important part of the planning process.

Where to Start

Sequencing LATAM approvals with your FDA pathway isn't complicated in principle. It requires knowing your FDA pathway before you design your protocol, selecting jurisdictions based on both approval timelines and site capability, and building your evidence package to FDA's expectations from the first day of enrollment.

If you're approaching that planning window, the bioaccess® FIH-12™ program is structured specifically for this sequence. Learn more at bioaccessla.com.

• Why EDC Selection Looks Different for FIH Studies
• The Core Requirements for a FIH-Ready EDC
  • 21 CFR Part 11 Compliance
  • ISO 14155 Compatibility for Medical Device Trials
  • Fast Configuration and Startup
  • Multi-Site and Multi-Country Data Collection
  • Regulatory Submission Export Formats
• What to Evaluate Beyond the Feature List
  • Vendor Experience with Early-Phase Studies
  • Data Management Support Model
  • Integration with Your CRO's Workflow
• Platforms Commonly Used in Early-Phase Trials
• The Biggest Mistakes Sponsors Make with EDC Selection
• How EDC Fits Into a FIH Program
• FAQs

Your electronic data capture system isn't a back-office detail when you're running a first-in-human trial. It's the infrastructure that determines whether your dataset is FDA-submittable or a rework project. Pick the wrong platform and you'll spend months cleaning data that should have been clean from day one.

This guide covers what actually matters when selecting an EDC for a FIH study — not a 200-site Phase III, but an early-feasibility or first-in-human trial where your team is lean, your timeline is tight, and the data package you generate needs to hold up under FDA scrutiny.

Why EDC Selection Looks Different for FIH Studies

Most EDC comparisons are written for large-scale trials with dedicated IT teams, established data management departments, and long build timelines. FIH studies operate under different conditions.

You're typically working with a small investigator team, a limited subject count, and a protocol that may still be evolving close to site activation. You need a platform that configures quickly, doesn't require months of validation work before you can collect a single data point, and produces outputs that map cleanly to your regulatory submission format — whether that's an IDE, a 510(k) package, or an IND.

The compliance bar doesn't change. ICH-GCP standards apply regardless of study size. If your trial runs outside the US, FDA 21 CFR 812.28 governs how that foreign clinical data is accepted. Your EDC needs to support audit trails, access controls, and data integrity standards that will survive a regulatory review.

The Core Requirements for a FIH-Ready EDC

21 CFR Part 11 Compliance

This is non-negotiable. Any EDC used in a trial intended to support an FDA submission must meet 21 CFR Part 11 requirements for electronic records and electronic signatures — audit trails for every data entry and modification, role-based access controls, and validated software with documented testing.

If a vendor can't provide a current validation package and a 21 CFR Part 11 compliance statement, move on.

ISO 14155 Compatibility for Medical Device Trials

Medical device FIH studies follow ISO 14155, the international standard for clinical investigation of medical devices. Your EDC needs to support data collection structures that align with this standard: adverse event capture, device accountability, protocol deviation tracking, and investigator assessments that map to the endpoints defined in your clinical investigation plan.

Not every EDC vendor has experience with device trials. Many are built primarily for drug studies, where the data architecture looks different. Ask specifically about ISO 14155 support and request examples of prior device study builds.

Fast Configuration and Startup

A FIH study on a 12-month timeline cannot absorb a 16-week EDC build. The best platforms for early-phase device and biopharma studies offer library-based form building, pre-validated study templates, and configuration timelines measured in weeks. Look for vendors who can demonstrate how quickly they activate a study from a finalized protocol — and get a realistic timeline in writing before you sign.

Multi-Site and Multi-Country Data Collection

If your trial runs across sites in Panama, Colombia, El Salvador, Chile, or the Dominican Republic, your EDC needs to support multi-language data entry, local time zone handling, and site-level access controls. Data collected across different regulatory jurisdictions still needs to flow into a single, clean, centralized database.

This is especially relevant when site staff are working in Spanish and your data management team is reviewing in English. The platform needs to handle that workflow without introducing transcription risk.

Regulatory Submission Export Formats

Your EDC should export data in CDISC CDASH and SDTM formats — the standards FDA expects for data submissions. If it can't produce clean SDTM datasets, your data management team will be doing manual conversions, which adds time, cost, and the risk of errors entering your submission package. Confirm the export formats before you commit to a platform.

What to Evaluate Beyond the Feature List

Vendor Experience with Early-Phase Studies

A vendor's reference list matters. Ask how many FIH or Phase I studies they've supported, and specifically whether any involved medical devices or international sites. A platform built primarily for large Phase III oncology trials may not have the configuration flexibility or support model that works for a 15-subject FIH feasibility study.

Data Management Support Model

Some EDC vendors sell software only. Others offer managed data management services alongside the platform. For a startup running its first FIH trial, a fully managed model often makes more sense than purchasing a license and building out your own DM team. Understand what's included in the contract and what's billed separately before you sign.

Integration with Your CRO’s Workflow

If you're working with a CRO that manages data management as part of its engagement, your EDC selection may be partially dictated by that CRO's existing infrastructure. This is worth discussing early. A CRO with validated workflows built around a specific EDC platform will execute faster and with fewer errors than one adapting to an unfamiliar system mid-study.

At bioaccess®, data management is one of the nine workstreams covered under the FIH-12™ program. EDC setup, data monitoring, and preparation of the final evidence package are handled by the same team managing your protocol, your sites, and your regulatory submissions — not handed off to a separate vendor.

Platforms Commonly Used in Early-Phase Trials

This isn't an exhaustive market review, and the right choice depends on your specific protocol, budget, and CRO relationship. That said, a few platforms appear consistently in early-phase and FIH study contexts.

Medidata Rave is the most widely deployed EDC in clinical research globally. It has strong 21 CFR Part 11 compliance infrastructure and broad regulatory acceptance. The tradeoff is configuration complexity and cost — it's better suited to sponsors with experienced data management teams or CROs with deep Medidata expertise.

REDCap is widely used in academic and early-phase settings for its low cost and fast setup. It can be configured for 21 CFR Part 11 compliance, but that requires careful validation work. It's not a commercial EDC and lacks some of the enterprise support features larger trials need. For a lean FIH study with a strong data management team, it can work — but the validation burden needs to be managed carefully when the data is intended to support an FDA submission.

Veeva Vault EDC has gained adoption in recent years, particularly in biopharma. It integrates well with other Veeva modules and has strong audit trail and compliance features. Configuration is generally faster than Medidata for straightforward protocols.

Castor EDC is built specifically for early-phase and academic trials, with a faster setup model and strong multi-language support. It's used in international studies and has a compliance framework that supports 21 CFR Part 11. For FIH studies with international sites, it's worth evaluating.

OpenClinica has a strong compliance pedigree, particularly in studies requiring CDISC output. It has both a commercial and an open-source version; the commercial version includes the validation documentation needed for regulatory submissions.

The Biggest Mistakes Sponsors Make with EDC Selection

Selecting based on price alone. The cheapest platform often carries the highest total cost once you factor in configuration time, data cleaning, and conversion work at submission. A platform that produces clean SDTM output from day one is worth more than one that requires manual post-processing.

Treating EDC as a standalone decision. Your EDC choice affects your CRO, your data management team, your regulatory timeline, and your submission package. Make the decision in context, not in isolation.

Underestimating the validation requirement. Every EDC used in a regulated trial needs to be validated. If the platform isn't already validated for your use case, that work takes time and costs money. Build it into your timeline from the start.

Locking in a platform before your protocol is finalized. EDC configuration is driven by your data collection requirements, which come from your protocol. Starting the build before the protocol is stable leads to expensive amendments and delays.

How EDC Fits Into a FIH Program

A FIH study generates the foundational dataset your entire regulatory pathway depends on. The EDC is the system that captures, validates, and stores that data. Set it up correctly and your final data package is clean, audit-ready, and formatted for submission. Get it wrong and you're looking at data remediation that can delay your IDE or 510(k) by months.

The most efficient path is to select your EDC as part of your overall FIH program design — not as a separate procurement. When your CRO manages data management as an integrated workstream alongside protocol development, site activation, and regulatory submissions, the EDC configuration is built to match the protocol from the start.

That integration is part of what makes a structured FIH program different from assembling vendors independently. If you're evaluating CRO options, it's worth understanding how each handles data management and what EDC infrastructure they bring to the engagement.

FAQs

What is an EDC system in clinical trials?
An electronic data capture (EDC) system is software used to collect, manage, and store clinical trial data in a structured, validated digital format. It replaces paper case report forms and provides the audit trail and access controls required for regulatory submissions.

Does my EDC need to be 21 CFR Part 11 compliant for a FIH study?
Yes. Any EDC used in a trial intended to support an FDA submission must comply with 21 CFR Part 11, which governs electronic records and electronic signatures. This includes audit trails, role-based access, and validated software with documented testing.

Can I use REDCap for a trial intended to support an FDA submission?
REDCap can be configured to meet 21 CFR Part 11 requirements, but it requires careful validation work that the sponsor or CRO must manage. It doesn't come with built-in regulatory validation packages the way commercial platforms do, so the compliance burden is higher.

How long does EDC configuration typically take for a FIH study?
For a straightforward FIH protocol, commercial EDCs with template libraries can typically be configured in four to eight weeks. More complex protocols or custom builds take longer. Factor this into your overall study startup plan.

What data export formats does FDA expect for EDC submissions?
FDA expects CDISC-compliant formats — specifically CDASH for data collection standards and SDTM for submission datasets. Your EDC should produce these formats directly. If it can't, your data management team will need to perform conversions, which adds time and risk.

Does the EDC need to support multiple languages for international FIH studies?
If your trial runs at sites where staff work in a language other than English, multi-language data entry support is important. For studies conducted in Latin American countries, site staff typically work in Spanish. Clean data collection in the local language reduces transcription errors and simplifies data review.

How does EDC selection affect my FDA submission timeline?
A well-configured EDC that produces clean, CDISC-compliant data shortens the time between last patient visit and a submission-ready data package. A poorly configured one can add months of cleaning and reformatting. EDC selection is a direct input to your regulatory timeline — not a separate operational decision.

Choosing the right EDC for a FIH study comes down to one question: will this platform produce a clean, FDA-submittable dataset within your timeline? Get the compliance infrastructure right, align the platform with your protocol and your CRO's workflow, and treat EDC selection as part of your overall program design from day one.

If you're planning a first-in-human trial and want to understand how data management fits into a structured FIH program, bioaccess® manages all nine workstreams under one engagement — including EDC setup and data management — across its network of sites in Panama, Colombia, El Salvador, Chile, and the Dominican Republic.

• What the FDA Is Actually Asking
• The 510(k) Pathway: Substantial Equivalence
  • What "substantially equivalent" means in practice
  • Timeline and workload
• The PMA Pathway: Valid Scientific Evidence
  • What a PMA clinical program looks like
  • Timeline and investment
• Key Differences at a Glance
• The De Novo Pathway: A Third Option Worth Knowing
• How Pathway Choice Shapes Your FIH Study
• Aligning FIH Trial Design to Your Pathway
• Practical Questions to Ask Before You Choose
• When Founders Get This Wrong
• FAQs

Choosing between a 510(k) and a Premarket Approval (PMA) is one of the most consequential decisions a medical device founder makes. Get it right early, and your clinical strategy, budget, and investor timeline all line up. Get it wrong, and you may spend 18 months collecting data that doesn't satisfy the evidentiary standard your pathway actually requires.

This article breaks down the core differences between the two pathways, how to determine which applies to your device, and what that choice means for your first-in-human trial design.

What the FDA Is Actually Asking

Both pathways exist to answer the same fundamental question: is this device safe and effective enough to be on the US market? The difference lies in how much evidence the FDA needs to reach that answer — and that requirement flows directly from how your device is classified.

The FDA assigns every medical device to one of three classes based on patient risk.

• Class I devices carry low risk. Most are exempt from premarket review entirely.
• Class II devices carry moderate risk. Most reach market through the 510(k) pathway.
• Class III devices carry the highest risk — typically because they sustain or support life, are implanted, or present an unreasonable risk of illness or injury. These require PMA.

Your device's classification is the starting point for everything else.

The 510(k) Pathway: Substantial Equivalence

A 510(k) submission asks the FDA to clear your device by demonstrating substantial equivalence to a legally marketed predicate. You're not proving safety and effectiveness in isolation — you're showing your device performs comparably to something already on the market.

What “substantially equivalent” means in practice

Your device must share the same intended use as the predicate and either the same technological characteristics, or different characteristics that don't raise new safety or effectiveness questions. That framing matters because it shapes what kind of clinical data — if any — you actually need to collect.

Many 510(k) submissions rely primarily on bench testing, biocompatibility data, and performance testing. When clinical data is required, it's typically a focused study rather than a full pivotal trial.

Timeline and workload

The FDA's standard review period for a 510(k) is 90 days from acceptance, though total elapsed time often runs longer when the agency issues additional information requests. For a device with a clear predicate and strong bench data, the 510(k) can be a relatively fast path to market.

The risk is predicate selection. A weak or distant predicate invites a Not Substantially Equivalent determination — which can push you toward De Novo or PMA territory without warning.

The PMA Pathway: Valid Scientific Evidence

A PMA requires you to demonstrate reasonable assurance of safety and effectiveness through valid scientific evidence. There's no predicate to point to. The FDA evaluates your device on its own merits, which means your clinical dataset needs to stand alone.

This is the pathway for Class III devices: implantable cardiac devices, certain neurological implants, high-risk diagnostics, and others where failure could cause serious harm.

What a PMA clinical program looks like

A PMA typically requires at least one well-controlled pivotal trial — often with a statistically powered sample size, defined primary endpoints, and a comparator arm. The FDA's review of that data is rigorous, and the agency may convene an advisory panel for high-profile submissions.

The IDE (Investigational Device Exemption) is the mechanism that allows you to collect pivotal data in the first place. Before you enroll a single patient in a significant-risk device study, you need an approved IDE. That application itself requires preliminary safety data — which is exactly where a first-in-human or early feasibility study fits in.

Timeline and investment

PMA is a longer, more expensive process than 510(k). Total development timelines from first-in-human to PMA approval can run five to ten years for complex devices. The clinical program alone typically spans multiple phases: an early feasibility study to establish safety signals, followed by a pivotal trial to generate primary effectiveness data.

For a startup, that timeline has direct implications for how you structure your FIH study and what evidence you need before your next funding round.

Key Differences at a Glance

The De Novo Pathway: A Third Option Worth Knowing

If your device is genuinely novel, poses low to moderate risk, and has no valid predicate, De Novo is worth serious consideration. It creates a new device classification and, once granted, establishes your device as a predicate for future 510(k) submissions.

De Novo is not a shortcut. It requires more documentation than a standard 510(k), and the FDA's review period is longer. But for a first-of-kind device that doesn't belong in Class III, it's the appropriate route — and it avoids the burden of a full PMA.

How Pathway Choice Shapes Your FIH Study

Your regulatory pathway determines the evidentiary standard your clinical data must meet. That standard, in turn, determines what your first-in-human study actually needs to accomplish.

For a 510(k) device, your FIH study is often a relatively small early feasibility study designed to confirm safety signals and support predicate comparisons. Endpoints are narrower, enrollment targets are smaller, and the study can typically be completed faster.

For a PMA device, your FIH study is the first step in a longer clinical program. The FDA will evaluate it as part of the overall evidence package, and the data needs to be structured to support the IDE application for your pivotal trial. Endpoints, patient population, and follow-up duration all have to be designed with that pivotal study in mind from day one.

This is why FDA strategy alignment can't be an afterthought. Design your FIH study without anchoring it to your intended pathway, and you risk collecting data that doesn't move your program forward.

Aligning FIH Trial Design to Your Pathway

At bioaccess®, every study in the FIH-12™ program begins with FDA strategy alignment as the first of nine workstreams. The protocol is built around the sponsor's intended pathway — whether that's IDE, 510(k), De Novo, PMA, or HDE — so the clinical evidence package that comes out of the program is structured for the submission it needs to support.

Trials run in Panama, Colombia, El Salvador, Chile, and the Dominican Republic, where ethics and regulatory approvals are observed in 30 to 90 days, compared to 6 to 12 months in the US. That speed matters when your runway is finite and your next funding milestone depends on having human data in hand.

The FIH-12™ program delivers a submission-ready evidence package within 12 months. All data is structured for FDA acceptance under 21 CFR 812.28, which governs the use of foreign clinical data in US submissions.

Practical Questions to Ask Before You Choose

Before committing to a pathway, work through these with your regulatory team:

What is your device's intended use, and does it match an existing predicate? If yes, 510(k) is likely your starting point. If no, you're looking at De Novo or PMA.

What risk class does the FDA assign to devices with your intended use? The FDA's product classification database is the first place to check. If your device type is consistently Class III, PMA is your pathway regardless of predicate availability.

Have you had a Pre-Submission (Q-Sub) meeting with the FDA? A Pre-Sub is the most direct way to get the agency's early read on your classification and pathway. It's not binding, but it significantly reduces the risk of a wrong-pathway investment.

What does your clinical evidence need to show? For 510(k), you need to demonstrate comparability. For PMA, you need to demonstrate safety and effectiveness. These are different evidentiary standards that require different study designs.

What is your funding timeline? If you have 18 months of runway and need human data before a Series B closes, a PMA pivotal trial isn't achievable in that window. But a well-designed early feasibility study that supports your IDE application can be.

When Founders Get This Wrong

The most common mistake is assuming a 510(k) pathway because a similar device exists on the market. Predicate selection is more nuanced than it looks. A device with the same intended use but meaningfully different technology may not qualify as substantially equivalent — and a Not Substantially Equivalent determination late in the process is expensive.

The second common mistake is under-designing the FIH study for a PMA pathway. Founders sometimes treat the early feasibility study as a standalone safety check rather than as the foundation for a pivotal trial. When the pivotal trial IDE application reaches the FDA, gaps in the early data create delays that could have been avoided.

Both mistakes come down to the same root cause: regulatory strategy that starts too late.

FAQs

What is the main difference between a 510(k) and a PMA?
A 510(k) clears a device by showing it is substantially equivalent to a legally marketed predicate. A PMA approves a device based on valid scientific evidence of safety and effectiveness, without relying on a predicate. PMA applies to Class III devices and requires a full clinical program; 510(k) applies primarily to Class II devices and often requires limited or no clinical data.

Does a 510(k) device need clinical trials?
Not always. Many 510(k) submissions rely on bench testing, biocompatibility data, and performance testing. Clinical data is required when bench testing alone can't establish substantial equivalence, or when the device's intended use involves a clinical performance claim that needs human data to support it.

What is an IDE and when do you need one?
An Investigational Device Exemption (IDE) is FDA authorization to use an investigational device in a clinical study. You need an IDE for any significant-risk device study conducted in the United States. For PMA devices, the IDE is the mechanism that allows you to collect the pivotal trial data the FDA requires for approval.

Can a Class II device require PMA?
In rare cases, yes. The FDA can require a Class II device to go through PMA if it determines that general and special controls aren't sufficient to provide reasonable assurance of safety and effectiveness. This is uncommon but worth confirming for novel device types.

What is the De Novo pathway and how does it differ from 510(k) and PMA?
De Novo is a classification pathway for novel, low-to-moderate-risk devices with no valid predicate. It creates a new device type and establishes the device as a predicate for future 510(k) submissions. It requires more documentation than a standard 510(k) but is less burdensome than PMA — making it the right route for genuinely first-of-kind devices that don't pose Class III risk.

How does my FDA pathway choice affect my first-in-human study design?
Your pathway determines the evidentiary standard your clinical data must meet. A 510(k) FIH study typically needs to confirm safety and support predicate comparisons, with narrower endpoints and smaller enrollment. A PMA FIH study is the first step in a longer clinical program and must be designed with the pivotal trial in mind from the start — including endpoints, patient population, and follow-up duration.

How long does PMA approval typically take compared to 510(k)?
The FDA's standard review period for a 510(k) is 90 days from acceptance, though total elapsed time is often longer. For PMA, the FDA has 180 days from filing acceptance to act, but the full development timeline from first-in-human to PMA approval for complex devices can span several years — including the time required to complete a pivotal trial.

Pathway selection is a regulatory decision with clinical, financial, and strategic consequences. The earlier you align your FIH study design to your intended submission, the less time and capital you spend collecting data that doesn't move your program forward.

If you're mapping your device's regulatory strategy and want to understand how a structured FIH program fits into that plan, learn more at bioaccessla.com.

• What Is INVIMA and What Does It Regulate?
• INVIMA Clinical Trial Approval Timeline
  • Pre-Submission and Document Preparation
  • Institutional Ethics Committee (IEC) Review
  • INVIMA Scientific Review
  • Authorization Issuance
• Required Documents for INVIMA Clinical Trial Submission
• Common Causes of Delay in INVIMA Approvals
  • Incomplete or Incorrectly Formatted Submissions
  • Protocol Language and Translation Quality
  • Ethics Committee Timing Misalignment
  • Query Response Delays
  • Investigator and Site Documentation Gaps
  • Regulatory Classification Uncertainty for Devices
• How Colombia Compares to Other LATAM Jurisdictions
• What to Do If Colombia Is Still the Right Fit
• FAQs
• Plan Your Timeline Around the Approval Process, Not After It

Colombia is one of the most frequently considered Latin American markets for clinical trial expansion. It has a large patient population, established academic medical centers, and a reasonably mature research infrastructure. But for MedTech and biopharma sponsors evaluating where to run a first-in-human or early-feasibility study, INVIMA's approval process carries a reputation worth examining honestly before you commit budget and timeline to it.

This article covers how INVIMA clinical trial approvals actually work, what documents you need, how long the process takes, and where sponsors most often lose weeks or months to delays that could have been avoided.

What Is INVIMA and What Does It Regulate?

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia's national health regulatory authority. It oversees clinical trial authorization for drugs, biologics, and medical devices conducted on Colombian territory.

For clinical research, INVIMA operates under Decree 2378 of 2008 and Resolution 8430 of 1993, which establish the ethical and scientific framework for human research in Colombia. Device trials also intersect with INVIMA's medical device registration framework, adding a classification review layer depending on the investigational product.

INVIMA is not a passive registry. It conducts substantive scientific review of protocols — which is one reason timelines run longer than sponsors sometimes expect when they first look at Colombia as a LATAM option.

INVIMA Clinical Trial Approval Timeline

INVIMA's official review window is 30 to 60 business days from the date of an accepted submission. In practice, sponsors should plan for 4 to 9 months total elapsed time — from initial submission to authorization — once you account for document preparation, parallel institutional ethics committee (IEC) review, query resolution, and any resubmission cycles.

Here is how the timeline typically breaks down:

Pre-Submission and Document Preparation

Assembling the dossier usually takes 4 to 8 weeks before submission. This phase is consistently underestimated. Missing or incorrectly formatted documents are the single most common source of delay, and INVIMA will not begin its substantive review until the submission passes an administrative completeness check.

Institutional Ethics Committee (IEC) Review

Colombia requires IEC approval from a recognized ethics committee at each participating site before INVIMA will issue final authorization. IEC timelines vary by institution and depend on each committee’s meeting schedule. Some sponsors submit to both IEC and INVIMA simultaneously to compress the overall timeline; others wait for IEC approval first. Running them in parallel is more efficient, but it requires your protocol and consent forms to be finalized before either submission goes in.

INVIMA Scientific Review

Once the submission is accepted, INVIMA's scientific review team evaluates the protocol, investigator qualifications, site suitability, and the study's risk-benefit profile. This phase generates formal queries — called requerimientos — that the sponsor must respond to within a defined window. A single query round can add 4 to 8 weeks, and complex protocols sometimes generate two rounds.

Authorization Issuance

After satisfactory responses to all queries, INVIMA issues the clinical trial authorization. No subjects can be enrolled until this document is in hand.

Required Documents for INVIMA Clinical Trial Submission

The exact document list varies depending on whether the study involves a drug, biologic, or medical device, but the core dossier for most clinical trials includes:

• Clinical study protocol (in Spanish or with a certified Spanish translation)
• Investigator's Brochure (IB) or equivalent device description document
• Informed consent form(s) in Spanish, compliant with Resolution 8430
• Investigator CVs for principal investigators at each site
• Site qualification documentation (infrastructure, equipment, staff)
• Ethics committee approval letter from the IEC at each participating site
• Sponsor authorization letter and legal representation documentation for the sponsor's local representative or CRO
• Product dossier including manufacturing information, quality data, and preclinical safety summary
• Insurance or indemnification documentation covering trial participants
• INVIMA application form completed in the required format

For medical device trials specifically, INVIMA may also request the device's risk classification under Colombian regulation and, in some cases, prior regulatory clearance or CE/FDA status as supporting context.

All documents must be submitted through INVIMA's digital platform (VUE, Ventanilla Única Empresarial) in the required format. Paper submissions are no longer accepted for most trial types.

Common Causes of Delay in INVIMA Approvals

Knowing where approvals stall is more useful than knowing the official timeline. These are the delays sponsors run into most often:

Incomplete or Incorrectly Formatted Submissions

INVIMA's administrative completeness check is strict. A missing document, an incorrectly formatted file, or a translation that does not meet certification standards will result in the submission being returned. The review clock does not start until the submission clears this check.

Protocol Language and Translation Quality

The protocol and consent forms must be in Spanish. Machine-translated documents or low-quality translations regularly generate queries during scientific review — and errors in technical terminology can raise substantive scientific questions that take multiple rounds to resolve.

Ethics Committee Timing Misalignment

If IEC review at a site is delayed, INVIMA will not issue final authorization even if its own review is complete. Sponsors who treat IEC review as a sequential step after INVIMA review, rather than a parallel track, routinely add 6 to 10 weeks to their overall timeline.

Query Response Delays

INVIMA's formal queries must be answered within a specified window. Sponsors who are not organized to respond quickly — or who need to revise the protocol to address a query — can lose significant time. Each query round resets a portion of the review clock.

Investigator and Site Documentation Gaps

INVIMA scrutinizes investigator qualifications carefully. CVs that do not reflect relevant therapeutic area experience, or sites that lack documented GCP training records, frequently generate queries or requests for additional information.

Regulatory Classification Uncertainty for Devices

For medical device trials, INVIMA's classification of the investigational device under Colombian regulation can introduce uncertainty. If the device does not map cleanly to an existing Colombian classification, INVIMA may request additional technical documentation before proceeding with clinical trial review.

INVIMA review is one phase of site activation. For the full sequence, from protocol synopsis through translation, insurance, contracts and site initiation, see our phase-by-phase site activation timeline guide. bioaccess® runs first-in-human studies in Colombia now.

How Colombia Compares to Other LATAM Jurisdictions

For sponsors evaluating where to run a first-in-human or early-feasibility study, the INVIMA timeline is a meaningful planning input. The realistic 4 to 9 month window for clinical trial authorization in Colombia is significantly longer than what sponsors can achieve in certain other Latin American jurisdictions.

In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are typically observed in 30 to 90 days. That gap matters when your runway is tied to a Series A milestone or a board deadline. A 6-month difference in regulatory approval timing can determine whether you have data in hand before your next funding round closes.

This is one reason sponsors working with bioaccess® on FIH programs operate in those four jurisdictions rather than Colombia. The faster approval windows are not a workaround — Panama, El Salvador, Chile, and the Dominican Republic are established regulatory environments with qualified sites and data structured for FDA acceptance under 21 CFR 812.28 for foreign clinical data.

What to Do If Colombia Is Still the Right Fit

Some sponsors have specific reasons to run in Colombia: existing investigator relationships, a patient population with particular disease prevalence, or a market access strategy that makes Colombian data valuable beyond the FIH milestone. If that describes your situation, the practical steps to minimize delay are:

1. Start document preparation 3 to 4 months before your target submission date. Certified translations and site qualification packages take longer than most teams expect.
2. Run IEC and INVIMA submissions in parallel. Coordinate with your sites so ethics committee submissions go in at the same time as your INVIMA dossier.
3. Engage a local regulatory affairs consultant or CRO with active INVIMA experience. Familiarity with current query patterns and administrative requirements is worth more than general LATAM regulatory knowledge.
4. Finalize your protocol before submission. Amendments after submission restart portions of the review process.
5. Build query response capacity into your team. Assign a dedicated person to monitor INVIMA communications and coordinate responses within the required window.

FAQs

What is the official INVIMA review timeline for clinical trial authorization?
INVIMA's official review window is 30 to 60 business days from the date of accepted submission. In practice, total elapsed time from initial submission to authorization is typically 4 to 9 months when accounting for document preparation, IEC review, and query resolution rounds.

Does Colombia require ethics committee approval before INVIMA authorization?
Yes. INVIMA requires IEC approval from a recognized institutional committee at each participating site as part of the authorization process. Running IEC and INVIMA submissions in parallel is the most efficient way to manage overall timeline.

What language must clinical trial documents be submitted in for INVIMA?
The protocol, informed consent forms, and most supporting documents must be in Spanish. Certified translations are required for documents originally prepared in other languages. Low-quality translations are a common source of queries and delays.

Can a foreign sponsor submit directly to INVIMA without a local representative?
No. Foreign sponsors must designate a local legal representative in Colombia or engage a CRO with local legal standing to submit and manage the application on their behalf.

What is the most common reason INVIMA submissions are delayed?
Incomplete or incorrectly formatted submissions that fail the administrative completeness check are the most frequent cause. This prevents the substantive review clock from starting and can add weeks to the process before the sponsor receives any feedback.

How does INVIMA's timeline compare to other Latin American jurisdictions?
Colombia's realistic 4 to 9 month window is longer than what is achievable in jurisdictions like Panama, El Salvador, Chile, and the Dominican Republic, where ethics and regulatory approvals are typically observed in 30 to 90 days for clinical trials in those markets.

Is INVIMA clinical trial data accepted by the FDA?
Foreign clinical data submitted to the FDA must meet the requirements of 21 CFR 812.28 for investigational devices, or equivalent standards for drugs and biologics. Whether INVIMA-authorized Colombian trial data satisfies those requirements depends on study design, ICH-GCP compliance, and the specific submission context. Sponsors should confirm FDA alignment before initiating any study intended to support a US regulatory pathway.

Plan Your Timeline Around the Approval Process, Not After It

INVIMA is a capable regulatory authority, and Colombia is a legitimate clinical research market. But the approval timeline is not forgiving of late starts or incomplete submissions. If you are managing a startup runway, a 4 to 9 month regulatory approval window needs to be factored into your FIH planning from the moment you begin site selection — not after your protocol is finalized.

If your primary goal is getting first human data within a timeline that works for your next funding round, it is worth understanding all your jurisdiction options in Latin America before defaulting to Colombia. Learn more at bioaccessla.com.

WordPress category: Navigating Regulatory Landscapes in Latin America

• Why Protocol Development Is Different for FIH Medical Devices
• Step 1: Align on Your US Regulatory Pathway First
• Step 2: Define Study Objectives and Endpoints Precisely
• Step 3: Write Eligibility Criteria That Reflect Real Patient Populations
• Step 4: Design the Safety Monitoring Plan
• Step 5: Build the Statistical Analysis Plan Into the Protocol From the Start
• Step 6: Address Regulatory Submission Requirements for Your Target Jurisdiction
• Step 7: Write the Protocol Amendment Process Into the Document
• How the FIH-12™ Program Structures Protocol Development
• Common Protocol Development Mistakes in FIH Device Studies
• FAQs
• Start With the Right Foundation

WordPress Category: Navigating Regulatory Landscapes in Latin America

Writing a clinical trial protocol for a first-in-human (FIH) medical device study is not a documentation exercise. It is a strategic decision that shapes your regulatory pathway, your site selection, your enrollment timeline, and ultimately whether your data will be accepted by FDA. Get it right, and you have a submission-ready evidence package. Get it wrong, and you are rewriting sections after your first ethics review, burning weeks you cannot afford.

This walkthrough covers what founders and clinical operations leads need to understand before a single word of their protocol is drafted.

Why Protocol Development Is Different for FIH Medical Devices

FIH drug trials follow a relatively standardized dose-escalation framework. Medical device FIH studies are more variable. The protocol must account for device-specific risks, operator learning curves, procedural endpoints, and the regulatory route the sponsor intends to pursue — whether that is IDE, 510(k), De Novo, PMA, or HDE.

FDA's investigational device exemption guidance and ISO 14155:2020 — the international GCP standard for medical device trials — together define the architecture your protocol must satisfy. If your study will generate data used in a US submission, structuring under ISO 14155 from the start is not optional. It is how you ensure the data qualifies under FDA 21 CFR 812.28 for foreign clinical data acceptance.

That regulatory anchor needs to be set before protocol drafting begins, not after.

Step 1: Align on Your US Regulatory Pathway First

Before writing a single inclusion criterion, confirm which FDA pathway the study data will support. Protocol design follows from that answer.

• IDE pathway: Your protocol must satisfy FDA's investigational device exemption requirements. For studies conducted outside the US, you will need to demonstrate that the study design, GCP compliance, and data collection meet the standards FDA applies to foreign clinical data under 21 CFR 812.28.
• 510(k) or De Novo: The protocol must define substantial equivalence endpoints or performance criteria that map directly to your predicate or device classification.
• PMA or HDE: Expect a more rigorous statistical plan, longer follow-up windows, and a higher bar for safety documentation.

Drafting a protocol to a generic GCP standard without first confirming the regulatory pathway is one of the most common and costly mistakes in early-stage device development. You end up with data that is scientifically valid but regulatorily incomplete.

Step 2: Define Study Objectives and Endpoints Precisely

The primary objective of a FIH device study is typically safety and feasibility, not efficacy. That distinction matters for how you structure your endpoints.

Primary endpoints should capture:

• Device-related adverse events and serious adverse events (SAEs)
• Technical success at the procedural level
• Early performance indicators tied to the device's mechanism of action

Secondary endpoints might include:

• Subject-reported outcomes at defined follow-up intervals
• Imaging or biomarker data supporting performance claims
• Operator assessment of usability and handling

Be specific. "Safety will be assessed" is not an endpoint. "Incidence of device-related SAEs at 30 days post-procedure" is. Vague endpoints create ambiguity during data analysis and give ethics committees a reason to request revisions.

Step 3: Write Eligibility Criteria That Reflect Real Patient Populations

Overly restrictive eligibility criteria are the single largest driver of enrollment delays in FIH device trials. Founders often write criteria that reflect their ideal study subject rather than the patients who actually present at clinical sites.

A few practical guidelines:

• Anchor criteria to your intended indication. If your device is intended for a broad population, your criteria should not narrow to a subgroup so specific that enrollment stretches to 18 months.
• Exclude for safety, not convenience. Every exclusion criterion should have a documented safety or scientific rationale. Ethics committees will ask.
• Pressure-test criteria against site feasibility data. If your CRO has pre-qualified sites in your target geography, they should be able to tell you whether the criteria are achievable given the patient populations those sites actually see.

In jurisdictions like Panama, El Salvador, Chile, and the Dominican Republic, patient populations are often well-suited for FIH feasibility work, with disease prevalence and site infrastructure that support enrollment within realistic timelines. Even so, your criteria still need to match the site's actual patient flow.

Step 4: Design the Safety Monitoring Plan

For a FIH device study, the safety monitoring plan is not a boilerplate appendix. It is a core section that regulators and ethics committees scrutinize carefully.

Your plan should define:

• Stopping rules: Specific, measurable criteria that would pause or terminate the study
• DSMB or independent safety review: Whether one is required, how often it convenes, and what data it reviews
• Adverse event reporting timelines: Expedited reporting requirements for SAEs, including timelines to the sponsor, ethics committee, and regulatory authority
• Device deficiency reporting: ISO 14155 requires a clear distinction between adverse events and device deficiencies — your protocol needs to reflect that

Sponsors running multi-site studies increasingly use dedicated ICSR (Individual Case Safety Report) platforms to manage regulatory submissions across jurisdictions, which reduces the risk of missed reporting windows during active enrollment.

Step 5: Build the Statistical Analysis Plan Into the Protocol From the Start

Many early-stage sponsors treat the statistical analysis plan (SAP) as something to write after enrollment closes. That is the wrong sequence.

Your protocol should include, at minimum:

• Sample size justification: For FIH feasibility studies, this is often based on precision estimates rather than power calculations — but you still need a documented rationale
• Primary analysis method: How you will analyze your primary safety and feasibility endpoints
• Handling of missing data: Especially relevant for device studies with procedural endpoints where some subjects may not complete follow-up

FDA reviewers will look at whether your analysis was pre-specified. A post-hoc safety analysis carries less weight than one defined prospectively in the protocol.

Step 6: Address Regulatory Submission Requirements for Your Target Jurisdiction

If you are running your FIH study in Latin America, your protocol needs to satisfy both the local regulatory authority and FDA's foreign data acceptance standards simultaneously.

In the four jurisdictions where bioaccess® operates, ethics and regulatory approvals take 30 to 90 days. That speed advantage is only realized if your protocol is structured correctly from submission. A document that requires multiple revision cycles with MINSA/CNBI in Panama or SRS/CNEIS in El Salvador will erode the timeline advantage those jurisdictions offer.

Key requirements to address in the protocol:

• Informed consent language: Must satisfy local ethics committee requirements and be available in the local language
• Investigator qualifications: Document the PI's experience with the device type and procedure
• Site infrastructure requirements: Define what the site needs to have in place — equipment, staff, and follow-up capabilities
• Data management standards: If the data will be submitted to FDA, your EDC and data collection instruments need to meet the requirements for foreign clinical data acceptance under 21 CFR 812.28

Step 7: Write the Protocol Amendment Process Into the Document

FIH studies generate new information. Your protocol will almost certainly need at least one amendment — whether to adjust stopping rules based on early safety data, modify follow-up windows, or refine eligibility criteria after the first few enrollments.

Define the amendment process in the protocol itself:

• What types of changes require ethics committee re-approval versus administrative notification
• How protocol deviations will be documented and reported
• Who has authority to approve amendments on the sponsor side

Ethics committees in Latin American jurisdictions, like those anywhere, expect sponsors to have a clear governance process for protocol changes. Having it documented upfront prevents delays when an amendment is actually needed.

How the FIH-12™ Program Structures Protocol Development

For startups running their first device trial, the protocol development process described above is often unfamiliar territory. The FIH-12™ program at bioaccess® integrates protocol development as one of nine structured workstreams, alongside FDA strategy alignment, site activation, patient enrollment, data management, and final evidence package delivery.

One accountable team manages all nine workstreams, which means the protocol is written with the site network, enrollment feasibility, and submission requirements already factored in — rather than developed in isolation and handed off to execution teams who find problems later.

If you are 12 to 24 months from needing your first human dataset and want a preliminary view of your country route, timeline range, and evidence package requirements, the FIH Launch Planner at bioaccessla.com generates a preliminary estimate based on your device class in six questions.

Common Protocol Development Mistakes in FIH Device Studies

A few patterns appear repeatedly in early-stage device programs:

Starting protocol development before regulatory strategy is confirmed. The protocol should follow from the regulatory pathway, not the other way around.

Writing endpoints that cannot be measured at your sites. If your primary endpoint requires imaging equipment or lab infrastructure that your sites do not have, you have an enrollment problem before you start.

Underestimating the ethics committee review process. Even in fast-approval jurisdictions, a poorly structured protocol will generate questions that extend your timeline. The 30 to 90 day approval window in Panama, El Salvador, Chile, and the Dominican Republic assumes a submission-ready document.

Separating the statistical plan from the protocol. Pre-specified analysis is a credibility signal for FDA reviewers. Build it in from the start.

Treating the protocol as a static document. Plan for amendments. They are not a sign that the study is failing — they are a normal part of FIH execution.

FAQs

What is the difference between a clinical trial protocol for a medical device versus a drug?
Drug protocols typically follow dose-escalation frameworks with pharmacokinetic endpoints. Medical device protocols focus on procedural safety, technical success, operator performance, and device-specific adverse events. They must also comply with ISO 14155 for GCP — the applicable standard for medical device trials — rather than the ICH E6 framework used for drugs.

Does a FIH protocol written for a Latin American study need to meet FDA standards?
Yes, if the data will be used in a US regulatory submission. Under FDA 21 CFR 812.28, foreign clinical data is acceptable when the study was conducted under GCP standards equivalent to those FDA requires. Structuring the protocol under ISO 14155 and aligning data collection with FDA's foreign data acceptance requirements from the start is how you ensure the data is usable for your IDE or 510(k) submission.

How long does it typically take to develop a FIH protocol for a medical device?
Timelines vary based on device complexity, regulatory pathway, and how much pre-clinical data is already available to inform safety parameters. Within the FIH-12™ program, protocol development is one of nine structured workstreams managed by a single accountable team, with the goal of a submission-ready evidence package within 12 months from program start.

What happens if the ethics committee requests protocol revisions?
Revision requests are normal and should be anticipated. The key is having a protocol that is well-structured enough to minimize revision cycles. In the four jurisdictions where bioaccess® operates, the 30 to 90 day approval window assumes a submission-ready document. Poorly structured protocols extend that window and erode the timeline advantage those jurisdictions offer.

How should sample size be justified for a FIH feasibility study?
For FIH device studies, sample size justification is typically based on precision estimates or feasibility criteria rather than statistical power calculations. You need a documented rationale explaining why the number of subjects is sufficient to characterize safety and feasibility for the intended use. FDA reviewers will look for this justification in the protocol.

What is ISO 14155 and why does it matter for FIH device protocols?
ISO 14155:2020 is the international standard for good clinical practice in medical device investigations. It defines requirements for protocol content, ethics committee submissions, informed consent, adverse event reporting, and data management. Structuring your FIH protocol under ISO 14155 is how you demonstrate GCP compliance to both local regulatory authorities in Latin America and FDA when submitting foreign clinical data.

When should a Data Safety Monitoring Board be included in a FIH device protocol?
A DSMB is not required for all FIH device studies, but it is strongly advisable for studies involving novel mechanisms, high-risk device classifications, or vulnerable patient populations. The protocol should define whether a DSMB is included, how often it convenes, what data it reviews, and what authority it has to recommend study modifications or early termination.

Start With the Right Foundation

A clinical trial protocol is the document that every downstream decision in your study depends on. Site selection, enrollment planning, data management, ethics submissions, and the final evidence package all trace back to choices made during protocol development.

For medical device founders running their first FIH study, the most important thing to get right is the regulatory anchor. Know your FDA pathway before you write your first endpoint. Structure your data collection for foreign data acceptance from day one. And build your safety monitoring plan with the same rigor you would apply to a pivotal trial — because for many FIH studies, this data will eventually support one.

If you are in the early stages of planning your FIH program, bioaccess® manages protocol development as part of a fully integrated nine-workstream engagement across Panama, El Salvador, Chile, and the Dominican Republic, where regulatory approvals take 30 to 90 days.

• What Clinical Trial Data Management Actually Covers
• Why Data Management Decisions Affect Your Regulatory Outcome
• The Fragmentation Problem
• Questions to Ask a CRO Before You Commit
• How Data Management Fits Into the Broader FIH Workstream
• What "Submission-Ready" Actually Means
• The Regulatory Context for Foreign Clinical Data
• Practical Checklist Before Choosing a CRO for Data Management
• FAQs

WordPress Category: General

Data management is one of the least glamorous parts of running a first-in-human trial. It is also one of the most consequential. A clean, audit-ready dataset is what separates a submission-ready evidence package from a pile of files that need months of remediation before they can go anywhere near the FDA.

If you are a MedTech or biopharma founder evaluating CROs, how a prospective partner handles clinical trial data management will tell you a great deal about how the rest of the engagement will go.

This article covers what data management actually involves in an early-phase trial, the questions worth asking before you sign a contract, and the structural factors that shape data quality from day one.

What Clinical Trial Data Management Actually Covers

The term gets used loosely. In practice, clinical trial data management is the end-to-end process of collecting, cleaning, validating, and locking study data so it meets regulatory standards for submission.

For a first-in-human study, that process spans several distinct activities:

• Electronic Data Capture (EDC) setup and validation — building case report forms (CRFs) that map to your protocol endpoints and configuring the system to flag out-of-range values automatically
• Data entry and source data verification (SDV) — confirming that what was recorded at the site matches source documents
• Query management — identifying and resolving discrepancies between site-entered data and expected values
• Medical coding — applying standard dictionaries (MedDRA for adverse events, WHO Drug for concomitant medications) so your safety data is interpretable
• Database lock — the formal closure of the database after all queries are resolved, after which no changes can be made without documented justification
• Data transfer and archiving — packaging the final dataset in formats compatible with your regulatory submission

Each of these steps has its own timeline, personnel requirements, and documentation burden. When any one of them is handled by a separate vendor, coordination risk multiplies.

Why Data Management Decisions Affect Your Regulatory Outcome

The FDA does not just review your clinical findings. It reviews the integrity of the process that produced them. Under 21 CFR 812.28, foreign clinical data submitted in support of a US device application must meet the same quality standards as data collected domestically. That means your EDC configuration, audit trails, query logs, and database lock documentation all become part of the evidentiary record.

For a startup running a first-in-human study on a 12-to-18-month timeline, data management quality has a direct effect on whether your clinical study report is submission-ready or requires remediation. Remediation after database lock is expensive, time-consuming, and sometimes impossible without reopening the database — which itself requires a documented rationale.

Protocols built to ISO 14155 architecture include data management requirements as a defined component, not an afterthought. If your CRO cannot describe how their data management plan aligns with ISO 14155, that is a meaningful gap.

The Fragmentation Problem

Most early-phase sponsors underestimate how often data management gets split across vendors. A CRO may handle protocol development and site activation while a separate EDC vendor manages the database, a biostatistics firm owns the analysis plan, and a medical writing group produces the final report. Each handoff is a point of failure.

When the EDC vendor configures CRFs without input from the biostatistician, you get a dataset that technically captures the data but does not support the analysis you need. When the medical writing group receives the final dataset without context from the clinical team, the narrative in the study report may not align with the data tables. These are not hypothetical problems. They are common ones.

The practical question to ask any CRO: who owns data management within your organization, and at what point do external vendors enter the process?

Questions to Ask a CRO Before You Commit

Before issuing an RFP or signing a master service agreement, these questions will give you a clearer picture of how a CRO actually manages data:

1. What EDC platform do you use, and is it validated under 21 CFR Part 11?
21 CFR Part 11 governs electronic records and signatures in FDA-regulated trials. Any EDC system used in a study intended for FDA submission must meet these requirements. Ask for documentation.

2. Who writes the data management plan, and when?
The data management plan (DMP) should be finalized before the first patient is enrolled. If a CRO cannot walk you through their DMP process in detail, that is a flag.

3. How are queries generated and resolved?
Automated edit checks catch many discrepancies, but manual review by a clinical data manager is still necessary. Ask about turnaround time for query resolution and how unresolved queries get escalated.

4. What is your process for medical coding?
MedDRA and WHO Drug coding require trained personnel and version-controlled dictionaries. Ask which version they use and how coding decisions are documented.

5. How is the final dataset structured for regulatory submission?
If your intended pathway is a 510(k), De Novo, PMA, or IDE, your dataset needs to be organized to support that specific submission. A generic data export is not the same as a submission-ready data room.

6. Who has access to the database during the study, and how is access controlled?
Audit trail integrity depends on controlled access. Ask how the CRO manages user permissions and what happens when a site coordinator leaves mid-study.

7. What does database lock look like, and what is your timeline from last patient visit to locked database?
Some CROs take 90 days or more to lock a database after last patient visit. For a startup on a funding timeline, that gap matters more than most founders realize.

How Data Management Fits Into the Broader FIH Workstream

Data management does not exist in isolation. It is one workstream within a larger clinical operations structure, and its quality depends on decisions made well upstream — how the protocol was written, how sites were trained, how CRFs were designed, and how adverse events were captured in real time.

This is why the organizational structure of your CRO matters as much as their technical capabilities. When one accountable team manages protocol development, site activation, patient enrollment, and data management under a single engagement, the decisions that affect data quality are made with the downstream submission already in mind.

bioaccess® structures its FIH-12™ program around nine integrated workstreams, with data management as a defined component of the evidence package deliverable. The final output is a clinical study report and organized data room structured for the sponsor's next FDA regulatory step — not a raw dataset handed off to a third party.

What “Submission-Ready” Actually Means

Sponsors sometimes assume a locked database is the same as a submission-ready package. It is not.

A submission-ready evidence package includes the clinical study report, the statistical analysis, data tables and listings, the protocol and amendments, informed consent documentation, site qualification records, and an organized data room that an FDA reviewer or Pre-Sub meeting team can navigate without additional explanation.

Producing that package requires tight coordination between data management, biostatistics, medical writing, and regulatory strategy. When those functions are siloed, the package often requires significant assembly work after the study closes — adding weeks or months to the timeline.

For a startup 12 to 18 months from a funding milestone, that assembly time is not a minor inconvenience. It is a material risk to your Series B narrative.

The Regulatory Context for Foreign Clinical Data

Running a first-in-human study outside the US does not lower the bar on data management. Under 21 CFR 812.28, the FDA accepts foreign clinical data in support of device applications when it meets the same quality standards as domestic data — including audit trail integrity, source data verification documentation, and a data management plan that was in place before enrollment began.

This is not a formality. FDA reviewers do examine data management documentation during Pre-Sub meetings and IDE reviews. A data room missing query logs, lacking a signed DMP, or showing gaps in audit trail continuity will generate questions that slow your submission.

Practical Checklist Before Choosing a CRO for Data Management

Use this as a starting point when evaluating vendors:

• EDC system validated under 21 CFR Part 11
• Data management plan finalized before first patient enrolled
• Protocols built to ISO 14155 (for medical devices)
• MedDRA and WHO Drug coding with documented version control
• Audit trail intact and exportable
• Clear timeline from last patient visit to database lock
• Final dataset structured for your specific FDA pathway
• One team accountable for data management through submission, not a handoff to a third party

FAQs

What is clinical trial data management in the context of a first-in-human study?
It is the end-to-end process of collecting, cleaning, validating, and locking study data to meet regulatory standards. For a FIH study, that covers EDC setup, source data verification, query management, medical coding, database lock, and final dataset packaging for FDA submission.

Does the FDA review data management documentation for foreign clinical studies?
Yes. Under 21 CFR 812.28, foreign clinical data submitted in support of a US device application must meet the same quality standards as domestic data — including audit trail documentation, the data management plan, and query resolution records.

What is a data management plan, and when should it be written?
A data management plan (DMP) describes how data will be collected, validated, stored, and transferred throughout the study. It should be finalized before the first patient is enrolled. A DMP written after enrollment begins is a regulatory gap.

What is the difference between a locked database and a submission-ready evidence package?
A locked database is the final, closed dataset. A submission-ready evidence package includes the locked database plus the clinical study report, statistical analysis, data tables and listings, protocol documentation, and an organized data room structured for your specific FDA pathway.

How does fragmented vendor management affect data quality?
When EDC configuration, biostatistics, and medical writing are handled by separate vendors without a single accountable team, upstream decisions made by one vendor routinely create problems for the next. CRF design that does not account for the analysis plan is a common example. One integrated team reduces these handoff risks significantly.

What EDC standards apply to trials intended for FDA submission?
Any EDC system used in a study intended for FDA submission must comply with 21 CFR Part 11, which governs electronic records and electronic signatures. The system must maintain a complete audit trail, control user access, and support data export in formats compatible with regulatory review.

How long does it typically take to lock a database after last patient visit?
It varies by CRO and study complexity. Some organizations lock within 30 to 45 days; others take 90 days or more. For a startup on a funding timeline, the gap between last patient visit and a locked, submission-ready dataset is a material planning variable — one worth clarifying before you sign.

Data management is not where most founders spend their due diligence time when evaluating a CRO. It should be. The quality of your final evidence package is determined by decisions made at the protocol stage, executed through enrollment, and finalized at database lock. A CRO that treats data management as a downstream function rather than an integrated workstream will cost you time at the moment you can least afford it.

If you are planning a first-in-human study and want to understand how data management fits into a structured, submission-ready program, bioaccessla.com is a useful starting point.